<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Biotech Stock Analysis Report</title>
    <link rel="stylesheet" href="../css/report.css">
</head>
<body>
    <div class="container">
        <div class="back-link">
            <a href="../../index.html">‚Üê Back to Index</a>
        </div>
        <h1>Stock Analysis Report</h1>
        <div class="meta">
            <strong>Generated:</strong> November 21, 2025<br>
            <strong>Tickers Analyzed:</strong> ILMN, PACB, DNA, TWST, RXRX, MRNA
        </div>

        <h2>üìä Summary Dashboard</h2>
        
        <h3>Key Metrics Overview</h3>
        <table>
            <thead>
                <tr>
                    <th>Ticker</th>
                    <th>Market Cap</th>
                    <th>Forward P/E</th>
                    <th>Trailing P/E</th>
                    <th>Revenue (TTM)</th>
                    <th>Profit Margin</th>
                    <th>ROE</th>
                    <th>Quarterly Rev Growth</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td><strong>ILMN</strong></td>
                    <td>18.35B</td>
                    <td>24.04</td>
                    <td>26.93</td>
                    <td>4.16B</td>
                    <td class="positive">16.40%</td>
                    <td class="positive">31.20%</td>
                    <td>0.40%</td>
                </tr>
                <tr>
                    <td><strong>PACB</strong></td>
                    <td>532.87M</td>
                    <td>--</td>
                    <td>--</td>
                    <td>154.67M</td>
                    <td>0.00%</td>
                    <td class="negative">-205.90%</td>
                    <td class="negative">-3.80%</td>
                </tr>
                <tr>
                    <td><strong>DNA</strong></td>
                    <td>479.27M</td>
                    <td>--</td>
                    <td>--</td>
                    <td>200.56M</td>
                    <td class="negative">-188.00%</td>
                    <td class="negative">-50.02%</td>
                    <td class="negative">-56.40%</td>
                </tr>
                <tr>
                    <td><strong>TWST</strong></td>
                    <td>1.56B</td>
                    <td>--</td>
                    <td>--</td>
                    <td>376.38M</td>
                    <td class="negative">-20.63%</td>
                    <td class="negative">-16.43%</td>
                    <td class="positive">16.90%</td>
                </tr>
                <tr>
                    <td><strong>RXRX</strong></td>
                    <td>2.10B</td>
                    <td>--</td>
                    <td>--</td>
                    <td>60.18M</td>
                    <td>0.00%</td>
                    <td class="negative">-91.07%</td>
                    <td class="negative">-80.20%</td>
                </tr>
                <tr>
                    <td><strong>MRNA</strong></td>
                    <td>9.45B</td>
                    <td>--</td>
                    <td>7.06</td>
                    <td>2.22B</td>
                    <td class="negative">-139.61%</td>
                    <td class="negative">-29.32%</td>
                    <td class="negative">-45.40%</td>
                </tr>
            </tbody>
        </table>

        <div class="insights">
            <h3>Quick Insights</h3>
            <ul>
                <li><strong>Largest Market Cap:</strong> ILMN (18.35B) followed by MRNA (9.45B)</li>
                <li><strong>Best Profit Margin:</strong> ILMN (16.40%) - only profitable company</li>
                <li><strong>Highest Growth:</strong> TWST (16.90% quarterly revenue growth)</li>
                <li><strong>Most Profitable:</strong> ILMN (16.40% profit margin, 21.40% operating margin)</li>
                <li><strong>Best Value:</strong> MRNA (Trailing P/E: 7.06) - though currently unprofitable</li>
            </ul>
        </div>

        <h2>üìà Individual Company Profiles</h2>

        <div class="company-section">
            <h3>ILMN - Illumina Inc.</h3>
            <p><strong>Extracted:</strong> November 21, 2025, 12:24 UTC</p>

            <h4>Valuation Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Market Cap</td><td>18.35B</td></tr>
                    <tr><td>Enterprise Value</td><td>19.65B</td></tr>
                    <tr><td>Trailing P/E</td><td>26.93</td></tr>
                    <tr><td>Forward P/E</td><td>24.04</td></tr>
                    <tr><td>Price/Sales</td><td>4.41</td></tr>
                    <tr><td>Price/Book</td><td>7.71</td></tr>
                    <tr><td>EV/Revenue</td><td>4.58</td></tr>
                    <tr><td>EV/EBITDA</td><td>15.46</td></tr>
                </tbody>
            </table>

            <h4>Financial Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Revenue (TTM)</td><td>4.16B</td></tr>
                    <tr><td>Revenue Per Share</td><td>27.36</td></tr>
                    <tr><td>Quarterly Revenue Growth (YoY)</td><td>0.40%</td></tr>
                    <tr><td>Gross Profit</td><td>2.93B</td></tr>
                    <tr><td>EBITDA</td><td>1.27B</td></tr>
                    <tr><td>Net Income</td><td class="positive">703M</td></tr>
                    <tr><td>Earnings Per Share</td><td class="positive">4.46</td></tr>
                    <tr><td>Quarterly Earnings Growth (YoY)</td><td class="negative">-78.70%</td></tr>
                </tbody>
            </table>

            <h4>Profitability Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Profit Margin</td><td class="positive">16.40%</td></tr>
                    <tr><td>Operating Margin</td><td class="positive">21.40%</td></tr>
                    <tr><td>Return on Assets (ROA)</td><td class="positive">9.15%</td></tr>
                    <tr><td>Return on Equity (ROE)</td><td class="positive">31.20%</td></tr>
                </tbody>
            </table>
        </div>

        <div class="company-section">
            <h3>PACB - Pacific Biosciences of California, Inc.</h3>
            <p><strong>Extracted:</strong> November 21, 2025, 12:24 UTC</p>

            <h4>Valuation Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Market Cap</td><td>532.87M</td></tr>
                    <tr><td>Enterprise Value</td><td>934.29M</td></tr>
                    <tr><td>Trailing P/E</td><td>--</td></tr>
                    <tr><td>Forward P/E</td><td>--</td></tr>
                    <tr><td>Price/Sales</td><td>3.53</td></tr>
                    <tr><td>Price/Book</td><td>14.76</td></tr>
                    <tr><td>EV/Revenue</td><td>6.04</td></tr>
                    <tr><td>EV/EBITDA</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Financial Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Revenue (TTM)</td><td>154.67M</td></tr>
                    <tr><td>Revenue Per Share</td><td>0.52</td></tr>
                    <tr><td>Quarterly Revenue Growth (YoY)</td><td class="negative">-3.80%</td></tr>
                    <tr><td>Gross Profit</td><td>58.37M</td></tr>
                    <tr><td>EBITDA</td><td>--</td></tr>
                    <tr><td>Net Income</td><td class="negative">-503.63M</td></tr>
                    <tr><td>Earnings Per Share</td><td class="negative">-2.1300</td></tr>
                    <tr><td>Quarterly Earnings Growth (YoY)</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Profitability Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Profit Margin</td><td>0.00%</td></tr>
                    <tr><td>Operating Margin</td><td class="negative">-100.94%</td></tr>
                    <tr><td>Return on Assets (ROA)</td><td class="negative">-32.23%</td></tr>
                    <tr><td>Return on Equity (ROE)</td><td class="negative">-205.90%</td></tr>
                </tbody>
            </table>

            <div class="note">
                <strong>Note:</strong> PACB is a pre-profit company with negative earnings. The company is in the sequencing technology space and is investing heavily in R&D.
            </div>
        </div>

        <div class="company-section">
            <h3>DNA - Ginkgo Bioworks Holdings, Inc.</h3>
            <p><strong>Extracted:</strong> November 21, 2025, 12:24 UTC</p>

            <h4>Valuation Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Market Cap</td><td>479.27M</td></tr>
                    <tr><td>Enterprise Value</td><td>440.28M</td></tr>
                    <tr><td>Trailing P/E</td><td>--</td></tr>
                    <tr><td>Forward P/E</td><td>--</td></tr>
                    <tr><td>Price/Sales</td><td>2.39</td></tr>
                    <tr><td>Price/Book</td><td>0.86</td></tr>
                    <tr><td>EV/Revenue</td><td>2.44</td></tr>
                    <tr><td>EV/EBITDA</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Financial Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Revenue (TTM)</td><td>200.56M</td></tr>
                    <tr><td>Revenue Per Share</td><td>3.31</td></tr>
                    <tr><td>Quarterly Revenue Growth (YoY)</td><td class="negative">-56.40%</td></tr>
                    <tr><td>Gross Profit</td><td>131.31M</td></tr>
                    <tr><td>EBITDA</td><td>--</td></tr>
                    <tr><td>Net Income</td><td class="negative">-339.55M</td></tr>
                    <tr><td>Earnings Per Share</td><td class="negative">-6.18</td></tr>
                    <tr><td>Quarterly Earnings Growth (YoY)</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Profitability Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Profit Margin</td><td class="negative">-188.00%</td></tr>
                    <tr><td>Operating Margin</td><td class="negative">-227.29%</td></tr>
                    <tr><td>Return on Assets (ROA)</td><td class="negative">-15.55%</td></tr>
                    <tr><td>Return on Equity (ROE)</td><td class="negative">-50.02%</td></tr>
                </tbody>
            </table>

            <div class="note">
                <strong>Note:</strong> DNA (Ginkgo Bioworks) is a pre-profit synthetic biology platform company. The company shows significant revenue decline (-56.40%) and negative profitability metrics, indicating heavy investment in platform development.
            </div>
        </div>

        <div class="company-section">
            <h3>TWST - Twist Bioscience Corporation</h3>
            <p><strong>Extracted:</strong> November 21, 2025, 12:24 UTC</p>

            <h4>Valuation Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Market Cap</td><td>1.56B</td></tr>
                    <tr><td>Enterprise Value</td><td>1.40B</td></tr>
                    <tr><td>Trailing P/E</td><td>--</td></tr>
                    <tr><td>Forward P/E</td><td>--</td></tr>
                    <tr><td>Price/Sales</td><td>4.04</td></tr>
                    <tr><td>Price/Book</td><td>3.29</td></tr>
                    <tr><td>EV/Revenue</td><td>3.72</td></tr>
                    <tr><td>EV/EBITDA</td><td class="negative">-35.26</td></tr>
                </tbody>
            </table>

            <h4>Financial Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Revenue (TTM)</td><td>376.38M</td></tr>
                    <tr><td>Revenue Per Share</td><td>6.30</td></tr>
                    <tr><td>Quarterly Revenue Growth (YoY)</td><td class="positive">16.90%</td></tr>
                    <tr><td>Gross Profit</td><td>191M</td></tr>
                    <tr><td>EBITDA</td><td class="negative">-39.68M</td></tr>
                    <tr><td>Net Income</td><td class="negative">-77.67M</td></tr>
                    <tr><td>Earnings Per Share</td><td class="negative">-1.30</td></tr>
                    <tr><td>Quarterly Earnings Growth (YoY)</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Profitability Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Profit Margin</td><td class="negative">-20.63%</td></tr>
                    <tr><td>Operating Margin</td><td class="negative">-30.23%</td></tr>
                    <tr><td>Return on Assets (ROA)</td><td class="negative">-13.56%</td></tr>
                    <tr><td>Return on Equity (ROE)</td><td class="negative">-16.43%</td></tr>
                </tbody>
            </table>

            <div class="note">
                <strong>Note:</strong> TWST is a pre-profit company but shows positive revenue growth (16.90%), indicating potential path to profitability. The company operates in DNA synthesis technology.
            </div>
        </div>

        <div class="company-section">
            <h3>RXRX - Recursion Pharmaceuticals, Inc.</h3>
            <p><strong>Extracted:</strong> November 21, 2025, 12:24 UTC</p>

            <h4>Valuation Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Market Cap</td><td>2.10B</td></tr>
                    <tr><td>Enterprise Value</td><td>1.52B</td></tr>
                    <tr><td>Trailing P/E</td><td>--</td></tr>
                    <tr><td>Forward P/E</td><td>--</td></tr>
                    <tr><td>Price/Sales</td><td>37.23</td></tr>
                    <tr><td>Price/Book</td><td>2.01</td></tr>
                    <tr><td>EV/Revenue</td><td>35.08</td></tr>
                    <tr><td>EV/EBITDA</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Financial Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Revenue (TTM)</td><td>60.18M</td></tr>
                    <tr><td>Revenue Per Share</td><td>0.11</td></tr>
                    <tr><td>Quarterly Revenue Growth (YoY)</td><td class="negative">-80.20%</td></tr>
                    <tr><td>Gross Profit</td><td class="negative">-503.45M</td></tr>
                    <tr><td>EBITDA</td><td>--</td></tr>
                    <tr><td>Net Income</td><td class="negative">-715.54M</td></tr>
                    <tr><td>Earnings Per Share</td><td class="negative">-1.8400</td></tr>
                    <tr><td>Quarterly Earnings Growth (YoY)</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Profitability Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Profit Margin</td><td>0.00%</td></tr>
                    <tr><td>Operating Margin</td><td class="negative">-3,327.57%</td></tr>
                    <tr><td>Return on Assets (ROA)</td><td class="negative">-42.20%</td></tr>
                    <tr><td>Return on Equity (ROE)</td><td class="negative">-91.07%</td></tr>
                </tbody>
            </table>

            <div class="note">
                <strong>Note:</strong> RXRX is a pre-profit AI/bioinformatics company with very high Price/Sales ratio (37.23), indicating significant market expectations. The company shows extreme negative operating margin (-3,327.57%) and significant revenue decline (-80.20%), suggesting heavy R&D investment phase.
            </div>
        </div>

        <div class="company-section">
            <h3>MRNA - Moderna, Inc.</h3>
            <p><strong>Extracted:</strong> November 21, 2025, 12:24 UTC</p>

            <h4>Valuation Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Market Cap</td><td>9.45B</td></tr>
                    <tr><td>Enterprise Value</td><td>5.68B</td></tr>
                    <tr><td>Trailing P/E</td><td>7.06</td></tr>
                    <tr><td>Forward P/E</td><td>--</td></tr>
                    <tr><td>Price/Sales</td><td>4.26</td></tr>
                    <tr><td>Price/Book</td><td>1.01</td></tr>
                    <tr><td>EV/Revenue</td><td>2.58</td></tr>
                    <tr><td>EV/EBITDA</td><td>4.64</td></tr>
                </tbody>
            </table>

            <h4>Financial Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Revenue (TTM)</td><td>2.22B</td></tr>
                    <tr><td>Revenue Per Share</td><td>5.76</td></tr>
                    <tr><td>Quarterly Revenue Growth (YoY)</td><td class="negative">-45.40%</td></tr>
                    <tr><td>Gross Profit</td><td class="negative">-3.49B</td></tr>
                    <tr><td>EBITDA</td><td class="positive">1.22B</td></tr>
                    <tr><td>Net Income</td><td class="negative">-3.12B</td></tr>
                    <tr><td>Earnings Per Share</td><td class="negative">-8.06</td></tr>
                    <tr><td>Quarterly Earnings Growth (YoY)</td><td>--</td></tr>
                </tbody>
            </table>

            <h4>Profitability Metrics</h4>
            <table>
                <thead>
                    <tr>
                        <th>Metric</th>
                        <th>Value</th>
                    </tr>
                </thead>
                <tbody>
                    <tr><td>Profit Margin</td><td class="negative">-139.61%</td></tr>
                    <tr><td>Operating Margin</td><td class="negative">-25.59%</td></tr>
                    <tr><td>Return on Assets (ROA)</td><td class="negative">-15.49%</td></tr>
                    <tr><td>Return on Equity (ROE)</td><td class="negative">-29.32%</td></tr>
                </tbody>
            </table>

            <div class="note">
                <strong>Note:</strong> MRNA shows a low Trailing P/E (7.06) but negative profitability metrics, indicating post-pandemic revenue normalization. The company has significant revenue decline (-45.40%) but maintains strong EBITDA (1.22B), suggesting operational efficiency despite net losses.
            </div>
        </div>

        <h2>üîÑ Comparison Tables</h2>

        <h3>Valuation Comparison</h3>
        <table>
            <thead>
                <tr>
                    <th>Metric</th>
                    <th>ILMN</th>
                    <th>PACB</th>
                    <th>DNA</th>
                    <th>TWST</th>
                    <th>RXRX</th>
                    <th>MRNA</th>
                </tr>
            </thead>
            <tbody>
                <tr><td><strong>Market Cap</strong></td><td>18.35B</td><td>532.87M</td><td>479.27M</td><td>1.56B</td><td>2.10B</td><td>9.45B</td></tr>
                <tr><td><strong>Enterprise Value</strong></td><td>19.65B</td><td>934.29M</td><td>440.28M</td><td>1.40B</td><td>1.52B</td><td>5.68B</td></tr>
                <tr><td><strong>Trailing P/E</strong></td><td>26.93</td><td>--</td><td>--</td><td>--</td><td>--</td><td>7.06</td></tr>
                <tr><td><strong>Forward P/E</strong></td><td>24.04</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td></tr>
                <tr><td><strong>Price/Sales</strong></td><td>4.41</td><td>3.53</td><td>2.39</td><td>4.04</td><td>37.23</td><td>4.26</td></tr>
                <tr><td><strong>Price/Book</strong></td><td>7.71</td><td>14.76</td><td>0.86</td><td>3.29</td><td>2.01</td><td>1.01</td></tr>
                <tr><td><strong>EV/Revenue</strong></td><td>4.58</td><td>6.04</td><td>2.44</td><td>3.72</td><td>35.08</td><td>2.58</td></tr>
                <tr><td><strong>EV/EBITDA</strong></td><td>15.46</td><td>--</td><td>--</td><td class="negative">-35.26</td><td>--</td><td>4.64</td></tr>
            </tbody>
        </table>

        <h3>Financial Performance Comparison</h3>
        <table>
            <thead>
                <tr>
                    <th>Metric</th>
                    <th>ILMN</th>
                    <th>PACB</th>
                    <th>DNA</th>
                    <th>TWST</th>
                    <th>RXRX</th>
                    <th>MRNA</th>
                </tr>
            </thead>
            <tbody>
                <tr><td><strong>Revenue (TTM)</strong></td><td>4.16B</td><td>154.67M</td><td>200.56M</td><td>376.38M</td><td>60.18M</td><td>2.22B</td></tr>
                <tr><td><strong>Revenue Per Share</strong></td><td>27.36</td><td>0.52</td><td>3.31</td><td>6.30</td><td>0.11</td><td>5.76</td></tr>
                <tr><td><strong>Quarterly Rev Growth</strong></td><td>0.40%</td><td class="negative">-3.80%</td><td class="negative">-56.40%</td><td class="positive">16.90%</td><td class="negative">-80.20%</td><td class="negative">-45.40%</td></tr>
                <tr><td><strong>Gross Profit</strong></td><td>2.93B</td><td>58.37M</td><td>131.31M</td><td>191M</td><td class="negative">-503.45M</td><td class="negative">-3.49B</td></tr>
                <tr><td><strong>EBITDA</strong></td><td>1.27B</td><td>--</td><td>--</td><td class="negative">-39.68M</td><td>--</td><td>1.22B</td></tr>
                <tr><td><strong>Net Income</strong></td><td class="positive">703M</td><td class="negative">-503.63M</td><td class="negative">-339.55M</td><td class="negative">-77.67M</td><td class="negative">-715.54M</td><td class="negative">-3.12B</td></tr>
                <tr><td><strong>Earnings Per Share</strong></td><td class="positive">4.46</td><td class="negative">-2.1300</td><td class="negative">-6.18</td><td class="negative">-1.30</td><td class="negative">-1.8400</td><td class="negative">-8.06</td></tr>
                <tr><td><strong>Quarterly Earnings Growth</strong></td><td class="negative">-78.70%</td><td>--</td><td>--</td><td>--</td><td>--</td><td>--</td></tr>
            </tbody>
        </table>

        <h3>Profitability Comparison</h3>
        <table>
            <thead>
                <tr>
                    <th>Metric</th>
                    <th>ILMN</th>
                    <th>PACB</th>
                    <th>DNA</th>
                    <th>TWST</th>
                    <th>RXRX</th>
                    <th>MRNA</th>
                </tr>
            </thead>
            <tbody>
                <tr><td><strong>Profit Margin</strong></td><td class="positive">16.40%</td><td>0.00%</td><td class="negative">-188.00%</td><td class="negative">-20.63%</td><td>0.00%</td><td class="negative">-139.61%</td></tr>
                <tr><td><strong>Operating Margin</strong></td><td class="positive">21.40%</td><td class="negative">-100.94%</td><td class="negative">-227.29%</td><td class="negative">-30.23%</td><td class="negative">-3,327.57%</td><td class="negative">-25.59%</td></tr>
                <tr><td><strong>Return on Assets (ROA)</strong></td><td class="positive">9.15%</td><td class="negative">-32.23%</td><td class="negative">-15.55%</td><td class="negative">-13.56%</td><td class="negative">-42.20%</td><td class="negative">-15.49%</td></tr>
                <tr><td><strong>Return on Equity (ROE)</strong></td><td class="positive">31.20%</td><td class="negative">-205.90%</td><td class="negative">-50.02%</td><td class="negative">-16.43%</td><td class="negative">-91.07%</td><td class="negative">-29.32%</td></tr>
            </tbody>
        </table>

        <h2>üìù Analysis Notes</h2>

        <div class="insights">
            <h3>Key Observations</h3>
            <ul>
                <li><strong>Market Leaders:</strong> ILMN dominates with the largest market cap (18.35B) and is the only profitable company in this biotech pipeline analysis. MRNA follows with 9.45B market cap but shows post-pandemic revenue normalization.</li>
                <li><strong>Growth Companies:</strong> TWST shows the only positive revenue growth (16.90%) among the group. Most companies show negative revenue growth, indicating either R&D investment phase or market challenges.</li>
                <li><strong>Valuation Insights:</strong> RXRX has extremely high Price/Sales ratio (37.23), indicating significant market expectations for AI-driven drug discovery. MRNA shows attractive Trailing P/E (7.06) but negative profitability. DNA has the lowest Price/Book ratio (0.86), potentially indicating undervaluation or market concerns.</li>
                <li><strong>Profitability Leaders:</strong> ILMN is the only profitable company with positive margins across all metrics. All other companies are pre-profit, typical for biotech companies in R&D phase. RXRX shows extreme negative operating margin (-3,327.57%), indicating heavy investment in platform development.</li>
                <li><strong>Biotech Pipeline Context:</strong> This analysis covers companies across the biotech investment pipeline: Sequencing (ILMN, PACB), AI/Bioinformatics (RXRX), Synthetic Biology Platforms (DNA), and mRNA Therapeutics (MRNA). Most companies are in capital-intensive R&D phases, consistent with the biotech investment thesis.</li>
            </ul>
        </div>

        <div class="footer">
            <p>
                <strong>Data Source:</strong> Yahoo Finance<br>
                <strong>Extraction Date:</strong> November 21, 2025<br>
                <strong>Original Data:</strong> stock_data_20251121_122508.json
            </p>
            <p style="margin-top: 15px;">
                <em>This report was automatically generated from Yahoo Finance data. All figures are as of the extraction date and may have changed since then.</em>
            </p>
        </div>
    </div>
</body>
</html>

